Risk of venous thromboembolism in women with polycystic ovary syndrome: A population-based matched cohort analysis

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 2, 2013, Pages

  Bird, Steven T ^a,b   Hartzema, Abraham G ^b   Brophy, James M ^c   Etminan, Mahyar ^d   Delaney, Joseph A C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE ORGANIZATION; MORBIDITY; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84873396245     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.120677     Document Type: Article

References (20)

1. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril 2012;97:28-38.
2. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;1:19-25.
3. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
4. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6.
5. Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347-63.
6. Baillargeon JP, McClish DK, Essah PA, et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005;90:3863-70.
7. Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010;82:139-46.
8. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006;85:436-40.
9. Falsetti L, Pasinetti E. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyprterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 1995;74:56-60.
10. Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999;50:517-27.
11. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005;90:5711-6.
12. Bird ST, Pepe SR, Etminan M, et al. The association between drospirenone and hyperkalemia. BMC Clin Pharmacol 2011;11:23.
13. Bird ST, Wei L, Brophy JM, et al. Irritable bowel syndrome and drospirenone-containing oral contraceptives; a comparativesafety study. Curr Drug Saf 2012;7:8-15.
14. Etminan M, Delaney JA, Bressler B, et al. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011;183:899-904.
15. Health IMS. LifeLink Health Plan Claims Database: overview and study design issues. Little Rock (AK): University of Arkansas for Medical Sciences; 2010. Available: www.uams.edu/TRI/hsrcore/Lifelink-Health-Plan-Claims-Data- DesignIssues-wcost-April2010[1].pdf (accessed 2012 Nov. 15).
16. Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002;3:4.
17. Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423
18. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6.
19. Seeger JD, Loughlin J, Eng PM, et al. Risk of thromboembolism in women taking ethinyestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93.
20. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 2007;22:317-22.